Abstract: Lung cancer is the leading cause of cancer-related death and patients most commonly present with incurable metastatic disease. National guidelines recommend screening for high-risk patients with low-dose computed tomography (LDCT), but this approach has limitations including high false positive rates. Activity-based nanosensors (ABNs) detect dysregulated proteases in vivo and release a reporter to provide a urinary readout of disease activity. Here, we demonstrate the translational potential of ABNs by coupling ABN multiplexing with intrapulmonary delivery to detect early-stage lung cancer in an immunocompetent, genetically engineered mouse model (GEMM). The design of the multiplexed panel of sensors was informed by comparative transcriptomic analysis of human and mouse lung adenocarcinoma data sets and in vitro cleavage assays with recombinant candidate proteases. When employed in a Kras and Trp53 mutant lung adenocarcinoma mouse model, this approach confirmed the role of metalloproteases in lung cancer and enabled accurate early detection of disease, with 92% sensitivity and 100% specificity.
Introduction
Lung cancer is the most common cause of cancer-related death (25.3% of cancer deaths in the U.S), with dismal 18.6% five-year survival rates 1 . Key to this high mortality is the fact that 57%
of lung cancer patients have distant spread of disease at the time of diagnosis 1 . Because patients with regional or localized disease have six-to 13-fold higher five-year survival rates than patients with distantly spread disease 1 , significant effort has been dedicated to improving diagnostic sensitivity. Screening with low-dose computed tomography (LDCT) is recommended in high-risk patients (adults aged 55 to 80 with a 30 pack-year smoking history 2 ) and enables a relative reduction in mortality of 20% when compared to the previous standard, chest radiography 3 . However, these screening tests are expensive 4 , have high false positive rates 3 (~96% 3 ) and potentially expose patients to biopsy-related complications, raising concern for overdiagnosis and increased healthcare-associated cost burden 5, 6 .
Great strides in the field of molecular diagnostics have yielded promising approaches that may be used in conjunction with LDCT for lung cancer screening. Circulating tumor DNA (ctDNA) has emerged as a promising tool for noninvasive molecular profiling of lung cancer [7] [8] [9] [10] .
However, the presence of ctDNA has been shown to scale with tumor burden and there are fundamental sensitivity limits for early stage disease 7,10,11 . To achieve high-sensitivity detection of ctDNA in stage I-II cancer patients, it is estimated that large (>80 mL) blood volumes would be needed with current methodologies, potentially limiting the widespread adoption of this approach 12 . Similarly, circulating tumor cells (CTCs) may be detected in patients with advancedstage non-small cell lung cancer (NSCLC), but the sensitivity of CTCs for detection of nonmetastatic disease remains low at present [13] [14] [15] [16] . Finally, transcriptional profiling of bronchial brushings can enhance the diagnostic sensitivity of bronchoscopy alone, even for peripheral and early-stage pulmonary lesions, an approach that leverages the "field of injury" that results from smoking and other environmental exposures 6, 17 . However, as with any invasive procedure, bronchoscopy carries the risk of attendant complications such as pneumothorax 18 .
Rather than relying on imaging techniques or detection of endogenous biomarkers in circulation, we have developed a class of "activity-based nanosensors" (ABNs) that monitor for a disease state by detecting and amplifying activity of aberrant proteases to generate urinary reporters [19] [20] [21] [22] [23] [24] . Protease activity is dysregulated in cancer, and proteases across catalytic classes play a direct role in all of the hallmarks of cancer, including tumor growth, angiogenesis, invasion, and metastasis [25] [26] [27] [28] [29] [30] . ABNs leverage dysregulated protease activity to overcome the insensitivity of previous biomarker assays, amplifying disease-associated signals generated in the 4 tumor microenvironment and providing a highly concentrated urine-based readout. We have previously explored the sensitivity of this approach via mathematical modeling 31 and cell transplant models 23 . However, to drive accurate diagnosis in a heterogeneous disease, a diagnostic must also be highly specific. Here, we explore the potential to attain both sensitive and specific early disease detection through multiplexing of 14 ABNs in an immunocompetent GEMM, which better recapitulates key aspects of human disease and allows for evaluation of diagnostic accuracy at the earliest stages of tumorigenesis. To this end, we established intrapulmonary ABN delivery as a means of eliminating activation in blood and off-target organs (reducing noise), while maximizing delivery to the target organ (increasing signal) ( Fig. 1A-B ).
After cleavage of ABN substrates by proteases in the lung, reporters rapidly entered the urine via the blood, where they were quantified by mass spectrometry (Fig. 1C-D) . Finally, we leveraged a machine learning classification algorithm, termed random forest, to achieve diagnostic sensitivity of 92% and specificity of 100% in detecting early-stage disease in a genetically engineered, Kras
and Trp53 mutant mouse model of lung adenocarcinoma (Fig. 1E) .
Results

Proteases are overexpressed in a Kras and Trp53 mutant mouse model of lung adenocarcinoma
Common driver mutations of NSCLC in humans are those that activate KRAS (10-30%) or inactivate function of TP53 (50-70%) 32 . To examine the ability of ABNs to detect lung cancer in a relevant mouse model, we selected a genetically driven model of adenocarcinoma (a type of NSCLC that accounts for 38% of all cases of lung cancer 33 ) that incorporates mutations in these genes. This extensively characterized model uses intratracheal administration of virus expressing Random forest classification is performed on a training cohort of mice and subsequently tested on an independent validation cohort in order to provide a positive or negative diagnosis of malignancy. 34 .
In anticipation of our use of the KP model to validate ABNs in vivo, we sought to characterize protease expression in tumor-bearing KP mice to nominate protease targets. To that end, we selected a recently published RNA-Seq dataset that profiled KP tumors across disease stages, and we used it to identify overexpressed secreted protease genes 35 . In this study, tumor cells expressing a fluorescent reporter had been isolated by FACS and profiled by RNA-Seq. We pooled samples from metastatic (T met , n = 9), non-metastatic (T non-met , n = 10), and early stage (KP-Early, n = 3) tumors, as well as Kras-mutant, Trp53-intact (K, n = 3) tumors and identified proteases that were overexpressed in tumor cells relative to normal lung cells (n = 2) ( Fig. 2A ).
Because this dataset was derived from FACS-purified tumor cells, it failed to take into account contributions from the KP tumor microenvironment. In addition, it was limited in its representation of early-stage disease. We therefore analyzed an additional gene expression dataset profiling the K model 36 , which is transcriptionally similar to early-stage KP tumors and human lung adenomas 35 . Significance analysis of microarrays (SAM) was used to identify proteases with increased expression in K tumors relative to normal lungs 37 (Fig. 2B ).
Proteases overexpressed in the KP mouse model are relevant to human lung adenocarcinoma
To ensure that ABNs were tuned to address human lung adenocarcinoma (LUAD)-associated proteases [38] [39] [40] (Fig. 2C, top) . Of the 20 most highly upregulated proteases, nine were metalloproteases, 11 were serine proteases, and several overlapped with proteases overexpressed in KP tumors (Fig. 2C, bottom) .
We then sought to assess whether proteases associated with benign lung diseases could confound the specificity of ABNs for lung cancer. 43 ; none of the 10 proteases included in the analysis classified benign lung diseases from healthy lungs with an AUC greater than 0.6. In contrast, classification efficiency in LUAD reached above 0.9 in eight out of ten cases ( fig. S2B-D) . The finding that genes upregulated in LUAD are not overexpressed in COPD or ILD may be due to our use of NAT as "normal" tissue when nominating proteases for the panel, as NAT is known to harbor inflammatory gene expression changes that distinguish it from "true normal" tissue 44 . 9 Therefore, the genes of the LUAD protease panel are more likely to be specific to cancer, rather than inflammation or other nonspecific disease-associated processes.
To assess whether the proteolytic landscape of the KP model recapitulates that of human lung cancer, we performed gene set enrichment analysis (GSEA) 45 in the TCGA dataset using the top 20 overexpressed proteases in the KP model (Fig. 2D) . GSEA assesses the extent to which a particular gene set (S) is enriched in a gene expression dataset by rank-ordering all genes in the dataset and iterating through the list, increasing the enrichment score each time a gene in S is encountered, and decreasing it otherwise. This approach revealed significant enrichment of 14 of the top 20 KP-expressed protease genes in human lung adenocarcinoma, yielding a maximum enrichment score of 0.455 (P = 0.0002).
A panel of proteases overexpressed in human and mouse lung adenocarcinoma enables robust classification of human disease
A set of 15 proteases overexpressed across all or a subset of the mouse and human datasets was then selected as a "LUAD protease panel", consisting of six metallo-, seven serine, and two aspartic proteases ( 
Cleavage of multiplexed substrate panel follows class-specific patterns
We have previously designed and validated hundreds of peptide sequences as protease substrates, leveraging known catalytic specificities of different protease families, published datasets, and substrate sequences in databases like cutDB and MEROPS 46, 47 . We nominated 14 of these substrates in an effort to encompass the cleavage preferences of metalloproteases (MP), serine proteases (SP), and aspartic proteases (AP), all of which were included in our LUAD protease panel, and characterized the catalytic reactivity of each protease-substrate pair. We 
Pulmonary-delivered nanoparticles distribute throughout the lung and reach the tumor periphery
The lung efficiently and rapidly exchanges compounds with the bloodstream owing to high surface area and very thin barriers; human adult lungs have an area of ~100 m 2 and, in alveoli, type I cells can be <0.1 µm thick 48 . Inhaled molecules and particles cross into the bloodstream by passive diffusion, transcytosis, or paracytosis, with rate and route of transit largely dependent on size and hydrophobicity 48 .
To adapt the ABN platform for highly sensitive and specific detection of early-stage lung cancer, we sought to circumvent background protease activity present in the blood and off-target organs, which can nonspecifically liberate reporters, by administering the nanosensors via localized intrapulmonary, rather than systemic intravenous, delivery. We built ABNs using a 40 kDa eight-arm poly(ethylene glycol) (PEG-8 40kDa ) nanoparticle coupled to protease substrates bearing terminal mass-encoded reporters (Fig. 1B) . Similarly sized PEG particles have been shown to remain in the lung with half-lives of several hours and relatively little phagocytosis 49 ;
consequently, we anticipate that the ABNs are largely free to sample extracellular lung protease activity over the time period during which we monitor urinary reporter accumulation. To assess biodistribution of ABNs following intrapulmonary delivery, we labeled the PEG-8 40kDa scaffold with a near-infrared dye, VivoTag750, delivered the nanoparticles to mice by intratracheal (IT) intubation or intravenous (IV) injection, and collected organs after 60 minutes (Fig. 4A ).
Fluorescence imaging revealed deep delivery of nanoparticles to all lung lobes in mice receiving IT particles, but negligible delivery to other organs ( Fig. 4B-C) . In contrast, only 14% of organ fluorescence was confined to the lung in the IV-delivered group. In terms of absolute delivery of ABNs, lung fluorescence in the IT group was 263 times greater than liver fluorescence (P < 0.0001), while lung fluorescence was 30% lower than liver fluorescence in the IV group. As blood is a rich, non-specific proteolytic matrix and achieving organ-specific biodistribution of systemically delivered nanoparticles remains difficult, IT ABNs offer distinct advantages over IV-delivered variants.
To assess microscopic distribution of the ABN scaffold within the lung following IT delivery, we labeled the PEG-8 40kDa scaffold with biotin and administered the nanoparticles to healthy mice by intratracheal intubation. Lungs were collected from mice 20-30 minutes post-IT delivery, fixed, and stained for biotin. While lungs from untreated mice were negative for biotin (Fig. 4D, top) , lungs from mice that received the scaffold demonstrated broad distribution of nanoparticles throughout the lung (Fig. 4D , bottom left) and specifically within terminal alveoli (Fig. 4D, bottom right) .
We then administered biotin-labeled PEG-8 40kDa scaffold in high grade KP tumor-bearing mice, by intratracheal intubation, to assess whether these particles are able to reach the site of disease. Again, while lungs from untreated KP mice were negative for biotin (Fig. 4E, top) , lungs from KP mice that received intrapulmonary delivery of the biotinylated scaffold demonstrated presence of nanoparticles at the margin of tumors where protease activity is relevant to disease growth and invasion [28] [29] [30] (Fig. 4E, bottom) .
Mass-encoded reporters filter from the lung to the urine via the blood and are detectable by mass spectrometry
In order to enable multiplexed detection of a broad spectrum of disease-associated proteases via a single in vivo administration of nanosensors, we conjugated each member of the LUAD substrate panel to a uniquely identifiable mass-encoded reporter (PP1-14; Table 1 ). Following 16 substrate proteolysis, the encoded reporters diffuse away from the nanoparticle scaffold and, due to their small size, efficiently cross into the bloodstream and are subsequently concentrated into the urine by glomerular filtration (Fig. 1B) . As previously described 19 S4C ). In contrast, the pharmacokinetic behavior of the free reporter following IT administration is suggestive of an initial phase of partitioning from the alveoli into the blood (peaking at 1 to 2 hours after delivery), followed by renal filtration from the blood.
Early-stage lung tumors in the KP model are detectable by ABNs
With the observation that IT delivery of mass-encoded reporters leads to their partitioning from lung to circulation and subsequent concentration in the urine, we sought to longitudinally monitor disease progression in KP mice with ABNs and benchmark their diagnostic performance against microCT. After initiating disease via administration of adenovirus, we monitored To characterize ABN performance relative to microCT in vivo, we administered all 14
protease-sensitive ABNs to the lungs of KP mice and healthy, age and sex-matched controls at 5, 7.5, and 10.5 weeks after tumor initiation. Mouse bladders were voided one hour after intrapulmonary delivery and all fresh urine produced during the subsequent hour (from 60-120 minutes after ABN administration) was pooled and collected. LC-MS/MS was performed and peak area ratios (defined as peak area of urinary reporter divided by peak area of spiked-in internal standard) of protease-sensitive reporters were mean-normalized within each urine sample to reduce mouse-to-mouse variation. Several reporters differentiated KP mice from the healthy control group, with some reporter differences becoming amplified over time (e.g. PP07, PP11) (Fig. 5B) . At 7.5 weeks and 10.5 weeks, 5/14 reporters were significantly different between KP and healthy mice (P adj < 0.05), while none of the reporters differed at 5 weeks ( fig.   S5 ). Three of the 5 reporters enriched in KP urine were the same at 7.5 and 10.5 weeks (PP02, PP03, and PP09), and these corresponded to peptides cleaved by metallo or both metallo and aspartic proteases in vitro. However, the most significantly enriched reporter in the urine of KP Unsupervised clustering by principal component analysis (PCA) succeeded in separating most KP and control mice at the 7.5 week and 10.5 week time points, but not at 5 weeks (Fig. 5C-E) .
Machine learning classification enables sensitive and specific disease diagnosis
As a step toward clinical translation of ABNs as a prospective diagnostic tool, we sought to demonstrate that a classifier could be trained on a subset of healthy and tumor-bearing mice and validated on an independent cohort. We trained a random forest classifier using the ABN reporter output from 50% of control mice tested at 5 weeks, 7.5 weeks, and 10.5 weeks, as well as from 50% of the KP mice tested at 7.5 weeks (Fig. 6A) . Random forest is a high-performance classifier, applicable to a wide variety of classification tasks, that generates a collection of decision trees (a "forest") that are sampled to produce classification results 50 . The classifier assigned a probability that each mouse belonged to either the KP cohort or the healthy control cohort (Fig. 6B , "Training" panel), achieving perfect separation of control and KP mice. We then locked and tested the classifier on an independent validation cohort consisting of classifier-naïve KP mice assayed at 5 weeks, 7.5 weeks, and 10.5 weeks post-induction, as well as the remaining control mice from each time point. KP mice were significantly more likely to be classified as "KP" than were control mice at 7.5 weeks and 10.5 weeks but not at 5 weeks (Fig. 6B, "Validation" panel). Accordingly, ROC analysis on the validation subset of this probability data revealed no classification power at 5 weeks (AUC 5wks = 0.58, P = 0.7) but significant classification at 7.5 weeks and 10.5 weeks (AUC 7.5wks = 0.96, P = 0.02; AUC 10.5wks = 0.95, P = 0.0005) (Fig. 6C) . With 100% specificity, ABNs exhibited sensitivity of 80% at 7. weeks (Fig. 5A) . Together, these data illustrate the power of multiplexed, lung-specific ABNs to intercept lung tumors early in disease development.
Discussion
In this work, we present an advance toward clinical translation of a new class of biomarkers, ABNs. We found that multiplexed ABNs, when delivered by intratracheal instillation, performed with diagnostic sensitivity of up to 92% and specificity of 100% for local, early-stage disease in an immunocompetent, genetically engineered, Kras and Trp53 mutant lung adenocarcinoma model (Fig. 6C) . Importantly, this model recapitulates the proteolytic landscape of human lung cancer ( Fig. 2D ) and is notable for overexpression of key enzymes associated with human disease, including MMP13 and several kallikreins ( Fig. 2A, C) . Our approach overcomes the intrinsic sensitivity limitation of blood-based diagnostic assays for early-stage disease by profiling disease activity directly within the tumor microenvironment and providing multiple steps of signal amplification 31 . We further ensure, by delivery via intratracheal instillation, that virtually all ABNs reach the lung and bypass nonspecific activation in off-target organs (Fig. 4B-C ).
Improved diagnostic tools are needed for lung cancer, as most patients present to the clinic when their disease has reached too advanced a stage for potentially curative therapy (e.g. surgical resection and/or chemoradiation) to be administered 1 . Screening by LDCT results in high false positive rates, leading many healthy patients to undergo unnecessary follow-up procedures that are costly and invasive 4 . Though there exist no widely accepted endogenous biomarkers for lung cancer 51 , several recently reported molecular diagnostic strategies hold promise. Multiplexed ctDNA profiling may be combined with protein biomarkers (as in CancerSEEK) to improve diagnostic accuracy for early-stage disease 52 . However, while the 23 sensitivity of this approach is high for certain cancer types, it is modest at 60% for lung cancer.
Analysis of volatiles in exhaled breath (by mass spectrometry or nanosensor arrays) has been shown to distinguish lung cancer patients from healthy controls, but further validation is needed to verify the specificity of these volatiles for malignant, rather than benign, pulmonary diseases 53, 54 . Combining ABNs with orthogonal diagnostic approaches that leverage ctDNA, protein biomarkers, CTCs, and/or volatiles may enhance diagnostic accuracy over any one modality alone.
This study represents a significant step toward clinical implementation of ABNs, S5 ). An intriguing hypothesis is that endogenous serine protease inhibitors may be downregulated during the maturation of primary tumors. Indeed, maspin is a serine protease inhibitor known to inhibit the metastatic and angiogenic potential of tumor cells 55, 56 and its transcript (Serpinb5) is significantly downregulated in pleural, soft tissue, and liver metastases relative to primary tumors in the KP model 35 . Dysregulated coagulation, which is driven by a cascade of serine proteases, has also been implicated in tumorigenesis and could drive ABN 24 activation in vivo 57 . Transcriptomic, proteomic, and ex vivo protease activity assays could be leveraged to rigorously define the mechanistic underpinnings of such stage-specific differences in ABN cleavage patterns.
In this work, we have demonstrated the sensitivity of intrapulmonary ABNs for local, early-stage lung cancer, but a challenge to overcome prior to clinical implementation is ensuring the specificity of ABNs for cancer over benign lung diseases. Though we provide preliminary evidence that proteases associated with lung cancer are not overexpressed in COPD or ILD on the RNA level ( fig. S2 ), further validation in mouse models and human samples will be needed.
We can further improve the specificity of ABNs for malignancy by screening a large, diverse panel of peptide substrates, via high throughput methods like substrate phage 58 or CLiPS 59 display, against ex vivo biospecimens from patients with LUAD, COPD, ILD, granulomas, and hamartomas 60 . Substrates can then be downselected on the basis of preferential cleavage by LUAD tissue to yield a highly specific panel. In parallel, we will also explore the compatibility of ABNs with pulmonary delivery systems like dry powder inhalers and nebulizers, with an eye toward clinical implementation.
In summary, intrapulmonary ABNs perform with high sensitivity and specificity for detection of local, early-stage lung cancer in a GEMM, via a non-invasive urine test. This performance is enabled by integrating across gene expression datasets of human and mouse lung adenocarcinoma to identify candidate proteases, screening these candidates against FRET-paired peptide substrates in vitro, and directly delivering ABNs incorporating these substrates into the lungs of mice. Future efforts will center on exploring protease biology at the earliest stages of lung cancer development in humans, designing ABNs that are highly specific for these proteases via high throughput screening methods, and evaluating their responsiveness in human 25 biospecimens. Clinically, ABNs may be used in conjunction with LDCT to enhance specificity and reduce the number of patients referred for invasive follow up procedures. With further optimization and validation studies, ABNs may one day provide an accurate, noninvasive, and radiation-free strategy for screening.
Materials and Methods
Study design
The goal of this study was to determine whether intrapulmonary administration of a multiplexed we were blinded to all characteristics but age, sex, and genotype. For random forest 26 classification, mice were randomly assigned to the training and validation cohorts using a randomly generated seed.
Gene expression analysis
Human RNA-Seq data was generated by the TCGA Research Network 36 were downloaded from GEO. Gene expression fold changes were determined by performing quantitative significance analysis of microarrays (SAM) using the "Standard" regression method, 100 permutations, and 10 neighbors for KNN 37 . 27 Pre-ranked gene set enrichment analysis (GSEA) was performed on the LUAD gene expression dataset from TCGA, using a gene set containing the top 20 overexpressed proteases in the KP model 35 . The pre-ranked list of log 2 (Fold Change) was generated previously by DESeq2. 10000 permutations by gene set were performed to calculate the P value. GSEA was performed via the GenePattern online software 62 . Enzyme cleavage rates were quantified as relative fluorescence increase over time normalized to fluorescence before addition of protease. Hierarchical clustering was performed in GENE-E, using fluorescence fold changes at 45 minutes.
Fluorogenic substrate characterization
Biodistribution studies
For all mouse experiments, anesthesia was induced by isofluorane inhalation (Zoetis) and mice were monitored during recovery. Biodistribution studies were performed in C57BL/6 mice.
VT750-NHS Ester (PerkinElmer) was coupled to 8-arm 40 kDa PEG-amine (PEG-8 40kDa -amine, JenKem) at a 4:1 molar ratio, reacted overnight, and purified by spin filtration. Mice were lightly anesthetized via isoflurane inhalation and PEG-8 40kDa -VT750 (50 uL volume, 5 uM concentration by VT750 absorbance) was administered by passive inhalation following 28 intratracheal intubation with a 22G flexible plastic catheter (Exel), as described elsewhere 34 .
Mice in the IV cohort were intravenously administered an equal dose of PEG-8 40kDa -VT750.
Animals were sacrificed by CO 2 asphyxiation 60 min post-inhalation/injection and organs were removed for imaging (LICOR Odyssey). Organ fluorescence was quantified in Fiji 63 by manually outlining organs, using the "Measure" feature, and taking the mean intensity.
Blood for pharmacokinetics measurements was collected using retro-orbital bleeds with 15 µL glass capillary collection tubes. Blood was diluted in 40 µL PBS with 5 mM EDTA to prevent clotting, centrifuged for 5 min at 5,000 x g, and fluorescent reporter concentration was quantified in 384-well plates relative to standards (LICOR Odyssey).
For immunohistochemical visualization of nanoparticles following IT administration, EZ-
Link NHS-Biotin (Thermo Scientific) was coupled to PEG-8 40kDa -amine at 2:1 molar ratio and reacted overnight, followed by spin filtration. Pulmonary delivery (50 uL volume, 10 uM concentration) was performed by intratracheal intubation. Fixation was performed 20-30 minutes later by inflating lungs with 10% formalin. Lungs were excised, fixed in 10% formalin at 4°C overnight, and embedded in paraffin blocks. 5 µm tissue slices were stained for biotin using the streptavidin-HRP ABC kit (Vector Labs) with DAB. Slides were scanned using the 20x objective of the Pannoramic 250 Flash III whole slide scanner (3DHistech).
Mouse model and in vivo characterization
Male B6/SV129 Kras LSL-G12D/+ ; Trp53 fl/fl (KP) mice between 18 and 30 weeks old were used for lung adenocarcinoma experiments. Tumors were initiated, as described previously 34 , by the intratracheal administration of 50 µL of adenovirus-SPC-Cre (2. 
LC-MS/MS reporter quantification
Liquid chromatography/tandem mass spectrometry was performed by Syneos Health (Princeton, NJ) using a Sciex 6500 triple quadrupole instrument. Briefly, urine samples were treated with UV irradiation to photocleave the 3-Amino-3-(2-nitro-phenyl)propionic Acid (ANP) linker and liberate the Glu-Fib reporter from residual peptide fragments. Samples were extracted by solidphase extraction and analyzed by multiple reaction monitoring by LC-MS/MS to quantify concentration of each Glu-Fib mass variant. Analyte quantities were normalized to a spiked-in internal standard and concentrations were calculated from a standard curve using peak area ratio (PAR) to the internal standard. Mean normalization was performed on PAR values to account for mouse-to-mouse differences in ABN inhalation efficiency and urine concentration.
